Molecular Templates Announces FDA Acceptance of IND Application for TAK-169, An Engineered Toxin Body Targeting CD38
June 17, 2019 08:00 ET
|
Molecular Templates, Inc.
TAK-169 Represents a Novel Mechanism of Action Targeting CD38Phase I Study to be Conducted in Relapsed/Refractory Multiple Myeloma Patients AUSTIN, Texas, June 17, 2019 (GLOBE NEWSWIRE) --...
Molecular Templates to Present at the Oppenheimer New York Oncology Insight Summit and the UBS Global Healthcare Conference
May 14, 2019 16:30 ET
|
Molecular Templates, Inc.
AUSTIN, Texas, May 14, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq: MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin...
Molecular Templates, Inc. Reports First Quarter 2019 Financial Results
May 13, 2019 16:01 ET
|
Molecular Templates, Inc.
AUSTIN, Texas, May 13, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular” or “Molecular Templates”), a clinical-stage oncology company focused on the discovery and...
Molecular Templates Announces FDA Acceptance of IND Application for MT-5111, An Engineered Toxin Body Targeting HER2
April 22, 2019 08:00 ET
|
Molecular Templates, Inc.
AUSTIN, Texas, April 22, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq: MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin...
Molecular Templates’ Presentations at the American Association of Cancer Research (AACR) Annual Meeting 2019 Highlight Evolution of ETB Platform
April 02, 2019 07:00 ET
|
Molecular Templates, Inc.
AUSTIN, Texas, April 02, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq: MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin...
Molecular Templates, Inc. Reports Fourth Quarter 2018 Financial Results
March 28, 2019 16:30 ET
|
Molecular Templates, Inc.
AUSTIN, Texas, March 28, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular” or “Molecular Templates”), a clinical-stage oncology company focused on the discovery and...
Molecular Templates Announces Initiation of Phase II Monotherapy Study of MT-3724 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients
March 28, 2019 08:00 ET
|
Molecular Templates, Inc.
AUSTIN, Texas, March 28, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq: MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin...
Molecular Templates to Present a Corporate Overview at the Cowen & Company 39th Annual and the Oppenheimer & Co. 29th Annual Health Care Conferences
March 05, 2019 16:30 ET
|
Molecular Templates, Inc.
AUSTIN, Texas, March 05, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM), a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin...
New Data on Molecular Templates’ Engineered Toxin Bodies to be Presented at the American Association of Cancer Research (AACR) Annual Meeting 2019
February 27, 2019 17:00 ET
|
Molecular Templates, Inc.
AUSTIN, Texas, Feb. 27, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq: MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin...
Molecular Templates Appoints Roger J. Waltzman, M.D., as Chief Medical Officer
February 19, 2019 16:30 ET
|
Molecular Templates, Inc.
AUSTIN, Texas, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM), a clinical-stage oncology company focused on the discovery and development of the company’s proprietary...